With the expected adoption of new ICH E6 Good Clinical Practice (GCP) guidelines just around the corner, it's no surprise that researchers are searching for a reliable and practical Risk-Based Monitoring (RBM) solution to make their trials safer, faster and more cost-efficient.
As the industry's leading EDC provider, Merge eClinical has teamed up with Remarque Systems to deliver the most advanced signal-driven RBM solution available. This unique integration of a purpose-built RBM application into a comprehensive EDC platform allows end-to-end study management in an audit-trailed RBM environment. A cloud-based, SaaS model, Remarque RBM fits right into your existing system, and no additional software or hardware is needed.
The Remarque RBM platform gives you real-time data exchange and robust risk assessment tools along with role-based views and functions. Plus, the integration with eCOS EDC means you can go beyond merely identifying risk: Now, you're prompted to take immediate action. You can modify, add or update key risk indicators, triggers and thresholds at any point to reflect changing trial conditions. And with all trial data at your fingertips, the time from study end to results is shorter than ever.
The integrated eCOS and Remarque RBM solution offers:
eCOS is the only EDC platform that offers this much power, exibility and functionality to conduct RBM trials. And just like eCOS, Remarque RBM is scalable, so it grows as you grow.
1 Motti, Eduardo F., M.D. “Risk-Based Monitoring: Have Investigators Been Served?” Pharmaceutical Outsourcing. March 26, 2015
If you would like to learn more about our eCOS platform, request a free Sandbox account or contact our team of experts at 866.387.4257.